Related Experiment Video
Updated: Jul 26, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
[EXPERIMENTAL PHARMACOKINETICS AND PHARMACODYNAMICS OF GB-115 DIPEPTIDE ANXIOLYTIC SUBSTANCES].
Micronized GB-115, a dipeptide anxiolytic, shows improved pharmacokinetics and bioavailability in rats compared to its crystalline form. The micronized substance also demonstrated superior anxiolytic effects in the elevated plus maze test.
Area of Science:
- Pharmacology
- Drug Development
- Medicinal Chemistry
Context:
- Anxiety disorders represent a significant global health burden.
- Novel anxiolytic agents with improved efficacy and bioavailability are needed.
- GB-115 is a novel dipeptide compound with potential anxiolytic properties.
Purpose:
- To evaluate the pharmacokinetics and pharmacological activity of GB-115 dipeptide anxiolytic.
- To compare the effects of crystalline versus micronized formulations of GB-115.
- To assess the anxiolytic potential of micronized GB-115 in an animal model.
Summary:
- Pharmacokinetic and pharmacological studies of GB-115 were conducted in male albino rats following oral administration.
- Micronized GB-115 exhibited enhanced pharmacokinetic parameters and bioavailability compared to the crystalline form.
- The micronized formulation demonstrated significant anxiolytic activity in the elevated plus maze test at a dose of 0.3 mg/kg, outperforming the crystalline substance.
Impact:
- The findings support the development of micronized GB-115 for pharmaceutical formulations.
- Micronized GB-115 shows promise as a novel dipeptide anxiolytic drug.
- Improved bioavailability and efficacy of micronized GB-115 could lead to better anxiety disorder treatments.
More Related Videos
05:42Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
10:16Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
Published on: March 12, 2019
Related Concept Videos
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Depolarizing Blockers: Pharmocokinetics
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacodynamics in Geriatric Patients: Effects of Age
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...